NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibitors in efficacy, safety, and patient-friendly delivery. The evolving NF1 landscape highlights how innovation ...

Detailed price information for Springworks Therapeutics Inc (SWTX-Q) from The Globe and Mail including charting and trades.

Why is that? That's because big pharmaceutical powerhouse Merck KGaA had agreed to acquire SpringWorks Therapeutics for a purchase price of $47 per share, which represents an equity value of $3.9 ...

Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare ...

Merck KGaA will acquire SpringWorks Therapeutics, a US biopharmaceutical company focused on developing treatments for rare tumors. 1 According to a press release from SpringWorks, this will allow the ...

SpringWorks said it would pay Merck a termination fee of $145.6 million if the deal falls through under certain circumstances. Stamford, Connecticut-based SpringWorks, which listed its shares in ...

Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business – – SpringWorks Therapeutics is a U.S.

Merck KGaA is building up its portfolio and pipeline with a $3.9 billion deal to acquire SpringWorks Therapeutics, a company with two FDA-approved rare tumor drugs, both of which offer the ...

Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German life ...

Merck acquires SpringWorks for $47/share, valuing it at $3.9B, with a 26% premium over its 20-day average price. SpringWorks' rare tumor treatments will boost Merck's revenue and help expand its U ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the Connecticut biopharma for an equity value of $3.9 billion, the companies ...

Merck said it would offer $47 a share in cash for the Nasdaq-listed SpringWorks. Merck's offer represents a 26% premium to SpringWorks' 20-day volume-weighted average price of $37.38 on Feb. 7 ...